Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144

5 Jul 2017

Abstract excerpt

Non-neutralizing IgG to the V1V2 loop of HIV-1 gp120 correlates with a decreased risk of HIV-1 infection but the mechanism of protection remains unknown. This V1V2 IgG correlate was identified in RV144 Thai trial vaccine recipients, who were primed with a canarypox vector expressing membrane-bound gp120 (vCP1521) and boosted with vCP1521 plus a mixture gp120 proteins from clade B and clade CRF01_AE (B/E gp120)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28678869
DOI: 10.1371/journal.pone.0180720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144PMID 28678869Read ↗

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized miceSemantic proximity Read ↗

FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells.Semantic proximity Read ↗

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialSemantic proximity Read ↗

Anti-V2 Antibody Deficiency in Individuals Infected With HIV-1Semantic proximity Read ↗

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.Semantic proximity Read ↗

Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic ActivitySemantic proximity Read ↗

Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.Semantic proximity Read ↗

Innate immune response to AAV-based gene therapy vectors: Mechanisms of complement activation and cytokine releaseSemantic proximity Read ↗

IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial.Semantic proximity Read ↗

Role of HIV-1 Envelope Glycoproteins Conformation and Accessory Proteins on ADCC ResponsesSemantic proximity Read ↗

Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.Semantic proximity Read ↗

An HIV Vaccine Protective Allele in FCGR2C Associates With Increased Odds of Perinatal HIV Acquisition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.